Risperidone in elderly schizophrenic patients - An open-label trial

被引：29
作者：
Berman, I [1 ]
Merson, A [1 ]
RachovPavlov, J [1 ]
Allan, E [1 ]
Davidson, M [1 ]
Losonczy, MF [1 ]
机构：
[1] HARVARD UNIV,SCH MED,CAMBRIDGE,MA 02138
来源：
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY | 1996年 / 4卷 / 02期
关键词：
D O I：
10.1097/00019442-199621420-00010
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
The authors assessed the safety and efficacy of risperidone in a group of elderly, patients with chronic schizophrenia and behavioral disturbances (N = 10). There were no clinically significant changes on physical examination. Also, schizophrenic symptoms and cognitive performance improved during risperidone administration. Patients showed a sufficient improvement in both areas to warrant a larger, double-blind study assessing the effects of risperidone on cognitive and psychiatric symptoms in elderly psychotic patients.
引用
收藏
页码：173 / 179
页数：7
相关论文
共 50 条
  • [21] A prospective open-label treatment trial of risperidone monotherapy in children and adolescents with bipolar disorder
    Biederman, J
    Mick, E
    Faraone, S
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S156 - S156
  • [22] One-year open-label trial of risperidone monotherapy in children with bipolar disorder
    Mick, E
    Biederman, J
    BIPOLAR DISORDERS, 2005, 7 : 78 - 78
  • [23] Treatment With Paliperidone in Children With Behavior Disorders Previously Treated With Risperidone: An Open-Label Trial
    Martin Fernandez-Mayoralas, Daniel
    Fernandez-Jaen, Alberto
    Munoz-Jareno, Nuria
    Calleja-Perez, Beatriz
    Laura Fernandez-Perrone, Ana
    Lopez Arribas, Sonia
    CLINICAL NEUROPHARMACOLOGY, 2012, 35 (05) : 227 - 230
  • [24] An Open-Label Study to Assess Monthly Risperidone Injections (180 mg) Following Switch from Daily Oral Risperidone (6 mg) in Stable Schizophrenic Patients
    Walling, David P.
    Shinde, Sunita N.
    Pogoda, Janice M.
    Kharidia, Jahnavi
    Laffont, Celine M.
    CLINICAL DRUG INVESTIGATION, 2024, 44 (04) : 251 - 260
  • [25] An open-label study of risperidone for the treatment of agitation in dementia
    Lavretsky, H
    Sultzer, D
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 1996, 4 (04) : 369 - 370
  • [26] Risperidone and cognitive functioning in elderly schizophrenic patients
    Reznik, I
    Paleacu, D
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2000, 8 (02) : 177 - 178
  • [27] An Open-Label Study to Assess Monthly Risperidone Injections (180 mg) Following Switch from Daily Oral Risperidone (6 mg) in Stable Schizophrenic Patients
    David P. Walling
    Sunita N. Shinde
    Janice M. Pogoda
    Jahnavi Kharidia
    Celine M. Laffont
    Clinical Drug Investigation, 2024, 44 : 251 - 260
  • [28] Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania
    Pavuluri, MN
    Henry, DB
    Carbray, JA
    Sampson, G
    Naylor, MW
    Janicak, PG
    JOURNAL OF AFFECTIVE DISORDERS, 2004, 82 : S103 - S111
  • [29] Open-label trial of nefazodone for depression in CHF patients
    Lespérance, F
    Frasure-Smith, N
    PSYCHOSOMATIC MEDICINE, 2001, 63 (01): : 163 - 164
  • [30] Open-label study of risperidone in children with bipolar disorder
    Biederman, J
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S314 - S314
12345